2016-03-11T00:00:00.000-05:00
preclinical development cost,-0.272188
ischemic stroke,-0.106741
adverse events,-0.317004
treatment,0.152528
license fee,0.361809
MultiStem patients,0.3348
acute neurological injury,-0.220631
acute respiratory distress,-0.0619913
study,-0.0645909
unmet medical need,0.644541
stroke,0.0224583
time,-0.0293616
ongoing clinical trial,0.367059
patients,-0.0334611
trial results,0.637517
myocardial infarction patients,-0.42905
MultiStem,-0.108734
trial,0.062246
debilitating ischemic stroke,-0.724315
early treatment,0.347591
future trial results,0.761153
NIH Stroke Scale,-0.344064
trial design,0.726536
new regulatory framework,0.7024
stroke specialists,0.545086
Chugai license fee,0.361809
stroke patients,0.052107
inflammatory cascade,-0.645852
Modified Rankin scale,-0.207976
right trial design,0.788297
Gil Van Bokkelen,-0.279268
contract revenues,0.219245
excellent outcome,0.490175
clinical trial,-0.179896
clinical rating scales,0.394296
respiratory distress syndrome,-0.0619912
natural adverse events,0.27267
Japan,0.600303
